Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

April 3, 2024

https://www.globenewswire.com/news-release/2024/04/03/2857341/0/en/Standard-BioTools-Announces-Multi-Year-Strategic-Engagement-with-Bristol-Myers-Squibb-for-Use-of-the-SomaScan-Platform-for-Translational-Medicine-Research.html

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers Squibb for use of the SomaScan® Platform as a tool for clinical trials in multiple therapeutic areas through 2026.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.